Young adults and adolescents who get COVID-19 may also exhibit symptoms of a complex, multisystem disorder previously known as chronic fatigue syndrome, three new case studies show.
With more of this age group being treated for COVID-19, clinicians are concerned they will start showing post-COVID or “long haul“ symptoms from their bouts with the virus.
The review in
Frontiers in Medicineprovides some of the first evidence that myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), may be one serious post-COVID problem.
“In the three patients studied all of whom had confirmed or highly probable COVID-19 infections early in the pandemic we observed ME/CFS-like symptoms within the first two weeks of illness,” says Peter Rowe, professor of pediatrics at Johns Hopkins University School of Medicine and director of the Chronic Fatigue Clinic at Johns Hopkins Children’s Center. “At six months following their illness, all three still met the criteria for being diagnosed
Story tip from Johns Hopkins experts on COVID-19
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Case Study Suggests Young People May Be Susceptible to Chronic Fatigue Following COVID-19
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
ProHealth
By Donna Gregory Burch • ProHealth.com • January 25, 2021
(
>2020 was a quiet year for the fibromyalgia community when compared to Lyme or ME/CFS. There were no major headlines, and yet thousands of researchers, physicians and advocates worked behind the scenes, inching toward better treatments, testing and quality of life for fibromyalgia patients.
Below is a summary of some of the most important fibromyalgia-related news stories from the past year. These small but mighty advances should lead to even more progress during 2021.
New Fibromyalgia Drugs Are in the Pipeline
NYX-2925:
In September, biopharmaceutical company Aptinyx, Inc. resumed patient recruitment for a phase 2 study of NYX-2925, a novel N-methyl-D-aspartate receptor modulator, after temporarily halting the trial in March due to the COVID-19 pandemic.